Zentaramine Injection

Adult dosage

For peripheral venous administration, administer slowly via intravenous drip 200 to 400 mL at a time. The infusion rate should be based on 120 minutes for 200 mL, aiming for approximately 10 g of amino acids over 60 minutes for optimal utilization in the body. For central venous administration, maintain continuous drip infusion of 400 to 800 mL per day according to high-calorie fluid methods. Co-administration with dextrose solutions is desirable.

Children's dosage

For peripheral venous administration, it should be infused slowly in children. For central venous administration, the dosage and infusion rate should be adjusted appropriately for children.

This medication must be used strictly under the guidance of a physician and should not be taken or discontinued arbitrarily. It should not be administered to patients with hepatic coma or those at risk, severe renal dysfunction, or certain metabolic disorders. Administration should also be avoided in patients with congestive heart failure, pulmonary edema, very low or absent urine output, and those with a history of myocardial infarction. Caution is required for patients with severe acidosis, congestive heart failure, or abnormal sodium or potassium levels, as well as those with impaired liver and renal function. This product contains sodium bisulfite, which may cause allergic reactions or asthma attacks, so special caution is necessary for asthmatic patients. During administration, adverse reactions such as rash, nausea, vomiting, cardiac symptoms, chills, fever, headache, and respiratory distress may occur; if symptoms arise, immediate consultation with healthcare professionals is advised. Rapid large volume administration may lead to metabolic acidosis or other serious complications, requiring vigilance. To maintain electrolyte balance in the blood, electrolyte status should be frequently monitored during large volume administration, and patients with diabetes should regularly check blood glucose levels. Awareness of possible interactions with other medications is important, particularly when used with tetracycline antibiotics. Safety in pregnant women has not been established, so administration should only occur when absolutely necessary and after consultation with healthcare professionals. When administering to children or elderly patients, adjustments to dosage and infusion rates may be necessary due to differing physiological functions, and blood ammonia levels should be monitored in children. Because this product contains electrolytes, rapid intravenous injection may lead to side effects; administration should be adjusted according to the patient’s temperature. Sterility should be meticulously maintained during the administration process, and the solution must not be used if discoloration or contamination occurs. For storage, do not open the packaging and do not use if the rubber stopper is damaged. This medication must be used according to the prescribed dosage and method, and any unusual symptoms should be reported to a healthcare provider immediately.

Serious side effects

Severe allergic reactions including anaphylaxis, asthma attacks, respiratory distress, respiratory arrest, shock, bronchospasm

Mild side effects

• Rash
• nausea
• vomiting
• chest discomfort
• palpitations
• tachycardia
• increased blood pressure
• acidosis
• chills
• fever

This medication should be stored in a sealed container to prevent the ingress of air or moisture, with a preferred temperature between 1 and 30 degrees Celsius for optimal preservation and to prevent deterioration.

Appearance

This injection is a colorless, transparent liquid in a glass vial with a rubber stopper for intravenous use.

Package unit

250mL/bottle